ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pancreatic Cancer
Non-Small-Cell Lung Carcinoma
Colorectal Cancer
Stomach Cancer
Cancer
Esophageal Cancer
Carcinoma

Adenocarcinoma trials near Hanyang, Seoul, KOR:

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...

Active, not recruiting
Gastric Cancer, Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: Ramucirumab
Drug: Paclitaxel

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Seoul, Korea, Republic of and 155 other locations

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (TroFuse-015)

(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...

Enrolling
Gastroesophageal Cancer
Drug: Rescue medication
Drug: Supportive care measures

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Seoul, South Korea and 165 other locations

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PRISM-1)

The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitab...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Drug: Gemcitabine
Drug: Nab-paclitaxel

Phase 3

Arcus Biosciences
Arcus Biosciences

Seoul, South Korea and 124 other locations

Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas

Minnelide Once a Day on Days 1 to 5, Days 8 to 12 and Days 15 to 19 Along with Abraxane Plus Gemcitabine in Patients with Metastatic Adenocarcinoma...

Enrolling
Metastatic Adenocarcinoma of the Pancreas
Combination Product: Minnelide

Phase 1

Minneamrita Therapeutics

Soeul, Korea, Republic of

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma...

Enrolling
Gastric Cancer
Drug: AZD0901
Drug: Capecitabine

Phase 2

AstraZeneca
AstraZeneca

Seoul, South Korea and 43 other locations

Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

esophageal adenocarcinoma.This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will b...

Enrolling
Gastroesophageal Adenocarcinoma
Esophageal Cancer
Drug: Levoleucovorin
Drug: Capecitabine

Phase 1, Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Seoul, South Korea and 42 other locations

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

with chemotherapy in treating adults with Claudin 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma...

Active, not recruiting
Metastatic Gastric Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Drug: placebo
Drug: zolbetuximab

Phase 3

Astellas
Astellas

Seoul, South Korea and 164 other locations

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

the treatment of participants with advanced or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, o...

Enrolling
Gastroesophageal Adenocarcinoma
Esophageal Cancer
Biological: Ramucirumab
Biological: Sacituzumab Tirumotecan

Phase 1, Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Seoul, South Korea and 42 other locations

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

paclitaxel in patients with HER2-high and in combination with tucatanib in patients with HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma...

Active, not recruiting
HER2-positive Gastric Cancer
Drug: Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel
Drug: Cinrebafusp alfa (PRS-343) in combination with tucatinib

Phase 2

Pieris Pharmaceuticals

Seoul, Korea, Republic of and 4 other locations

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection comp...

Enrolling
Metastatic Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: 5-fluorouracil (5-FU)
Drug: Cisplatin

Phase 3

BeiGene
BeiGene

Seoul, Seoul Teugbyeolsi, South Korea and 94 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems